To further explore the immunological impact of TV+TLR7 we performed ELISAs at week 4 after infection and prior to ART initiation, week 22 prior to vaccination, week 34 after priming with Ad48, week 52 after boosting with MVA, and 2 weeks prior to ATI. The gene discussed is TLR7; the disease is infection.